View the APVRS symposium on "Expert clinical insights: Continous delivery of anti-VEGF for the managament of nAMD"
Despite advances in the treatment of neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factor (anti-VEGF) therapies, in the real world many patients fail to reach the visual outcomes observed in clinical trials. This symposium delves into innovations in anti-VEGF delivery and the current treatment landscape in retinal diseases, provides an overview of the Port Delivery System with ranibizumab (PDS), outlines PDS clinical evidence of long-term maintenance of vision, highlights key surgical pearls for implantation of the PDS and refill-exchange procedures, and reviews a case study.